Want to see MBX full AI Analyst Report?

MBX Biosciences, Inc. (MBX) Price & Analysis

226 Followers

MBX Stock Chart & Stats

$33.77

-$0.30(-2.05%)

At close: Jan 08 4:00 PM EST

$33.77

-$0.30(-2.05%)

Day’s Range― - ―

52-Week Range$9.63 - $57.38

Previous CloseN/A

Volume52.29K

Average Volume (3M)886.37K

Market Cap

$2.63B

Enterprise Value$1.35B

Total Cash (Recent Filing)$439.98M

Total Debt (Recent Filing)$555.00K

Price to Earnings (P/E)―

Beta2.00

Next Earnings

Aug 06, 2026

EPS Estimate

-0.64

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.20

Shares Outstanding47,597,534

10 Day Avg. Volume1,141,652

30 Day Avg. Volume886,366

Financial Highlights & Ratios

PEG Ratio-0.46

Price to Book (P/B)3.12

Price to Sales (P/S)0.00

P/FCF Ratio-14.06

Enterprise Value/Market Cap0.51

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-6.04K

Enterprise Value/Ebitda-15.66

Forecast

1Y Price Target

$74.75

Price Target Upside121.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

EPS Forecast (FY)-2.81

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Pivotal Phase 2 Efficacy And Phase 3 PlanRobust Phase 2 canvuparatide efficacy with sustained one-year responders and a planned Phase 3 creates a durable clinical development pathway. This strengthens the company’s ability to seek regulatory approval, secure commercial partnerships, and justify continued R&D investment over the next several years.

Low Leverage And Stronger CapitalizationVery low debt and a materially improved equity base reduce solvency risk and provide strategic flexibility. A stronger capital structure improves ability to raise non-debt financing or partner on programs, lowering bankruptcy risk and supporting multi-year clinical plans.

Broad, Advancing Obesity And Metabolic PipelineAdvancement of a once-monthly GLP-1/GIP prodrug and nominations across obesity/metabolic programs diversify clinical risk. Multiple modalities and indications increase options for internal commercialization or partnering, aligning with structural growth in obesity/metabolic therapeutics.

Bears Say

Pre-revenue StatusBeing pre-revenue means the company lacks operating cash inflows to fund development, creating a multi-year dependence on external financing. This structural profile limits margin visibility, prevents internal reinvestment, and magnifies the commercial risk tied to clinical success.

Accelerating Cash BurnWorsening operating and free cash flow indicate accelerating cash consumption to fund trials. High, sustained burn shortens runway, raises dilution risk from equity raises or partner deals, and can materially constrain the firm’s ability to complete pivotal studies without external capital.

Widening Losses And Funding RiskMaterially widening net losses erode shareholder value and create persistent funding requirements. Even with low debt, continued losses necessitate future financings, which may dilute shareholders or impose partnership terms that limit strategic autonomy if trial timelines or outcomes slip.

MBX Biosciences, Inc. News

MBX Biosciences down 19% at $30.05 after announcing canvuparatide study results

08:19 EDT MBX Biosciences (MBX) down 19% at $30.05 after announcing canvuparatide study results Published first on TheFly...

19d ago

MBX

MBX Biosciences announces results from Avail, canvuparatide trials

MBX Biosciences (MBX) announced full results from the 12-week Avail Phase 2 trial and new one-year data from...

19d ago

MBX

Analyst Reiterates Buy on MBX, Maintains $91 Price Target on Canvuparade’s Once-Weekly Hypoparathyroidism Opportunity

Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on MBX Biosciences, Inc.. The associated price...

13d ago

MBX

MBX Biosciences unveils positive Phase 2 canvuparatide results

The latest announcement is out from MBX Biosciences, Inc. ( ($MBX) ). On June 12, 2026, MBX Biosciences...

19d ago

MBX

MBX Biosciences Shareholders Approve Directors and Auditor

An update from MBX Biosciences, Inc. ( ($MBX) ) is now available. MBX Biosciences, Inc., a publicly traded...

26d ago

MBX

MBX Biosciences price target raised to $56 from $50 at Stifel

Stifel raised the firm’s price target on MBX Biosciences (MBX) to $56 from $50 and keeps a Buy...

2M ago

MBX

MBX Biosciences price target raised to $70 from $66 at Barclays

Barclays raised the firm’s price target on MBX Biosciences (MBX) to $70 from $66 and keeps an Overweight...

2M ago

MBX

MBX Biosciences price target raised to $86 from $76 at Citizens

Citizens raised the firm’s price target on MBX Biosciences (MBX) to $86 from $76 and keeps an Outperform...

2M ago

MBX

MBX Biosciences price target raised to $70 from $50 at Truist

Truist analyst Srikripa Devarakonda raised the firm’s price target on MBX Biosciences (MBX) to $70 from $50 and...

2M ago

MBX

MBX Biosciences Phase 1 data supports once-monthly dosing for MBX 4291

MBX Biosciences (MBX) announced multiple updates on its obesity portfolio, including preliminary blinded Phase 1 data for MBX...

2M ago

MBX

MBX Biosciences Highlights Positive Phase 1 Obesity Data

MBX Biosciences, Inc. ( ($MBX) ) has issued an update. On May 11, 2026, MBX Biosciences reported preliminary...

2M ago

MBX

Advancing Pipeline and Key Data Catalysts Drive Analyst’s Bullish View on MBX

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on MBX stock, giving a Buy rating...

2M ago

MBX

MBX Biosciences reports Q1 EPS (51c), consensus (58c)

“We continue to make excellent progress across our pipeline in 2026, including advancement toward initiation of our Phase...

2M ago

MBX

MBX Biosciences appoints Mark Soued as chief commercial officer.

MBX Biosciences (MBX) announced the appointment of Mark Soued as chief commercial officer. Most recently, Soued served as...

2M ago

MBX

ALNY

MBX FAQ

What was MBX Biosciences, Inc.’s price range in the past 12 months?

MBX Biosciences, Inc. lowest stock price was $9.63 and its highest was $57.38 in the past 12 months.

What is MBX Biosciences, Inc.’s market cap?

MBX Biosciences, Inc.’s market cap is $2.63B.

When is MBX Biosciences, Inc.’s upcoming earnings report date?

MBX Biosciences, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 36 days.

How were MBX Biosciences, Inc.’s earnings last quarter?

MBX Biosciences, Inc. released its earnings results on May 07, 2026. The company reported -$0.51 earnings per share for the quarter, beating the consensus estimate of -$0.585 by $0.075.

Is MBX Biosciences, Inc. overvalued?

According to Wall Street analysts MBX Biosciences, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does MBX Biosciences, Inc. pay dividends?

MBX Biosciences, Inc. does not currently pay dividends.

What is MBX Biosciences, Inc.’s EPS estimate?

MBX Biosciences, Inc.’s EPS estimate is -0.64.

How many shares outstanding does MBX Biosciences, Inc. have?

MBX Biosciences, Inc. has 47,597,534 shares outstanding.

What happened to MBX Biosciences, Inc.’s price movement after its last earnings report?

MBX Biosciences, Inc. reported an EPS of -$0.51 in its last earnings report, beating expectations of -$0.585. Following the earnings report the stock price went up 8.064%.

Which hedge fund is a major shareholder of MBX Biosciences, Inc.?

Currently, no hedge funds are holding shares in MBX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

MBX Biosciences, Inc. Stock Smart Score

Neutral

Fundamentals

Return on Equity

-24.50%

Trailing 12-Months

Asset Growth

84.08%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

MBX Biosciences, Inc.

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.

MBX Biosciences, Inc. (MBX) Earnings & Revenues

Historic Earnings Reports

MBX Stock 12 Month Forecast

Average Price Target

$74.75

▲(121.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","51":"$51","92":"$92","30.5":"$30.5","71.5":"$71.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":91,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$91.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":74.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$74.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,30.5,51,71.5,92],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.65,35.29230769230769,39.934615384615384,44.57692307692308,49.21923076923077,53.86153846153846,58.503846153846155,63.146153846153844,67.78846153846155,72.43076923076924,77.07307692307693,81.71538461538461,86.3576923076923,{"y":91,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.65,34.04230769230769,37.434615384615384,40.82692307692307,44.21923076923077,47.61153846153846,51.003846153846155,54.396153846153844,57.78846153846153,61.18076923076923,64.57307692307691,67.96538461538461,71.3576923076923,{"y":74.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.65,32.6,34.55,36.5,38.45,40.4,42.35,44.3,46.25,48.2,50.15,52.1,54.05,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.75,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.07,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.97,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.29,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.78,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.65,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >